New Street Investor Relations

?? Introducing our New Website ?? We are excited to share the launch of our brand-new website, a project that reflects our commitment to serving our clients and their investors. This milestone would not have been possible without the exceptional expertise of Alden Marketing Communications whose team brought our vision to life in ways that exceeded all expectations. Their work has elevated our online presence with a beautifully designed platform that not only highlights our services but also encourages engagement. From creating a seamless user experience to incorporating call-to-action features that drive leads, their approach was nothing short of meticulous. Thank you to Maxwell Sherman & Lesley Guilmette and the rest of the team at Alden for helping us take this exciting step forward! Follow our new site here https://newstreetir.com/

Whats the difference between a sell-side analyst, a buy-side analyst, and a banking analyst? (And what are the buy-side, sell-side, and Chinese walls)? Time and again over the years I’ve heard first-time biotech executives get confused over the kind of analyst they’ve been talking to (and worse, some confuse banks with buy-side institutions as a result). The distinction however is vitally important because two classes of analyst exist on different sides of the Chinese wall from the third. Read more about it on our weekly blog:

We wanted to take a moment today to congratulate our client Rapport Therapeutics on their appointment of a new CMO Dr. Jeffrey Sevigny. Check out their latest press release below:

How Do You Build a Biotech’s Equity Research Coverage? (And Is There Such a Thing as Too Much Coverage?) Having an equity analyst take up coverage of your biotech (including their rationale, a recommendation and price target) costs money – either directly or indirectly. This is because equity analysts can be paid $1+ million a year, including bonus, depending on their prestige and the bank they work for (an analyst friend of mine gave me a sliding scale of $500k-$5M). In other words, they are not cheap. Read more about it on our blog.

Just in, my client Synedgen, Inc announced the publication of preclinical data that show MIIST305 mitigating gastrointestinal acute radiation syndrome (GI-ARS) injury and ameliorating radiation-induced gut microbiome dysbiosis in a murine model. Read more about it in their latest press release:

My client Neurona Therapeutics has just unveiled its Phase 3 EPIC study for NRTX-1001 in epilepsy. ? Based on alignment gained with FDA under the Regenerative Medicine Advanced Therapy (RMAT) designation, Neurona plans to conduct the Phase 3 EPIC (Epilepsy Cell therapy) trial as the primary basis for a future NRTX-1001 Biologics License Application. Read more about it on their website.

How Do Public Biotechs Know Who Owns Them? (And what are 13F, 13D and 13G reports, and transfer agents/registrars?) This week we are diving into the intricacies of public companies and unearthing ownership. It may sound odd, but the last time a biotech knows exactly who owns them is in the brief seconds before their first trade as a public company. Read more about it on our blog here:

How Do Public Biotechs Know Who Owns Them? (And what are 13F, 13D and 13G reports, and transfer agents/registrars?) This week we are diving into the intricacies of public companies and unearthing ownership. It may sound odd, but the last time a biotech knows exactly who owns them is in the brief seconds before their first trade as a public company. Read more about it on our blog here:

Should Biotechs Hire an (Internal) Investor Relations Officer or an (External) Investor Relations Agency? As an investor relations agency, you would be right in assuming that we have strong (and potentially biased) views to the question posed. Nevertheless, let’s talk seriously about the options available to biotechs and the choices they make. Read the full blog post on our website.

Congratulations to our client Revance on their completed takeover by Crown Laboratories.